PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, Dung T., Uram, Jennifer N., Wang, Hao, Bartlett, Bjarne R., Kemberling, Holly, Eyring, Aleksandra D., Skora, Andrew D., Luber, Brandon S. +27 more·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1500596

Cited by (1,079)

Items 901–1,000 of 1,079

Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer
Sumana Narayanan, Tsutomu Kawaguchi, Li Yan, Xuan Peng, Qianya Qi, Kazuaki Takabe · 2018 · Annals of Surgical Oncology
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Rosaria Condorelli, Fernanda Mosele, Benjamin Verret, Thomas Bachelot, Philippe Lucien Bedard, Javier Cortés, DM Hyman, Dejan Juric, Ian E. Krop, Ivan Bièche et al. · 2019 · Annals of Oncology
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells
Simone Lieb, Silvia Blaha-Ostermann, Elisabeth Kamper, Janine Rippka, Cornelia Schwarz, Katharina Ehrenhöfer-Wölfer, Andreas Schlattl, Andreas Wernitznig, Jesse Lipp, Kota Nagasaka et al. · 2019 · eLife
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang et al. · 2021 · Journal of Hematology & Oncology
The New Era of Immunotherapy in Gastric Cancer
Shogo Takei, Akihito Kawazoe, Kohei Shitara · 2022 · Cancers
Barriers and opportunities for gemcitabine in pancreatic cancer therapy
Beutel, Alica K., Halbrook, Christopher J. · 2023 · American Journal of Physiology-Cell Physiology
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability
Changqing Ma, Krishna Patel, Aatur Dilip Singhi, Bing Ren, Benjamin Zhu, Fyza Y. Shaikh, Weijing Sun · 2016 · The American Journal of Surgical Pathology
Immune and molecular correlates in melanoma treated with immune checkpoint blockade
Elizabeth H. Byrne, David E. Fisher · 2017 · Cancer
Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy
Si-Pei Wu, Ri-Qiang Liao, Hai‐Yan Tu, Wenjun Wang, Zhong‐Yi Dong, Shu‐Mei Huang, Wei‐Bang Guo, Lan-ying Gou, Huiwen Sun, Qi Zhang et al. · 2017 · Journal of Thoracic Oncology
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
Jakob Nikolas Kather, Niels Halama, Dirk Jaeger · 2018 · Seminars in Cancer Biology
Immune checkpoint inhibitors in cancer therapy
S. Eika, Liu Peng, Renato B. Baleeiro, R. Nicholas, Yuan Ming, Wang Yaohe · 2017 · Journal of Biomedical Research
Clinical utility of circulating tumor DNA for colorectal cancer
Hiroki Osumi, Eiji Shinozaki, Kensei Yamaguchi, Hitoshi Zembutsu · 2019 · Cancer Science
OncoTree: A Cancer Classification System for Precision Oncology
Ritika Kundra, Hongxin Zhang, Robert Sheridan, Sahussapont Joseph Sirintrapun, Avery Wang, Angelica Ochoa, Manda Wilson, Benjamin E Gross, Yichao Sun, Ramyasree Madupuri et al. · 2021 · JCO Clinical Cancer Informatics
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Nadeem Riaz, Jonathan J. Havel, Sviatoslav M. Kendall, Vladimir Makarov, Logan A. Walsh, Alexis Desrichard, Nils Weinhold, Timothy An-thy Chan · 2016 · Nature Genetics
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
Gerald Steven Falchook, Rom S. Leidner, Elizabeth Stankevich, Brian Piening, Carlo Bruno Bifulco, Israel Lowy, Matthew G. Fury · 2016 · Journal for ImmunoTherapy of Cancer
Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis
Jutta K. Huvila, Jennifer Pors, Emily F. Thompson, C. Blake Gilks · 2020 · The Journal of Pathology
Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts
Michele Bortolomeazzi, Mohamed Reda Keddar, Lucia Montorsi, Amelia Acha‐Sagredo, Lorena Gabriela Benedetti, Damjan Temelkovski, Subin Choi, Nedyalko Petrov, Katrina Todd, Patty T. Wai et al. · 2021 · Gastroenterology
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino, Gerardo Botti, Paul C. Lorigan, Giuseppe Valentino Masucci, Jason Hipp, Christine E. Horak, Ignacio Melero, Paolo A. Ascierto · 2016 · Drugs
Immunotherapy for Colorectal Cancer
Patrick McKay Boland, Wen Ma · 2017 · Cancers
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kyum Kim, Sumanta Kumar Pal, Daniel J. George, Tian Zhang · 2018 · Journal for ImmunoTherapy of Cancer
Rational combinations of immunotherapy with radiotherapy in ovarian cancer
Fernanda Gabriela Herrera, Melita B. Irving, Lana Elias Kandalaft, George Coukos · 2019 · The Lancet Oncology
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma
M.J.M. van Velzen, Sarah Derks, Nicole C.T. van Grieken, Nadia Haj Mohammad, Hanneke W.M. van Laarhoven · 2020 · Cancer Treatment Reviews
Biomarkers for Immunotherapy: Current Developments and Challenges
Kristen Renee Spencer, Jianfeng Wang, Ann Willman Silk, Shridar Ganesan, Howard L. Kaufman, Janice M. Mehnert · 2016 · American Society of Clinical Oncology Educational Book
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Antonia R. Sepulveda, Stanley R. Hamilton, Carmen Joseph Allegra, Wayne W. Grody, Allison M. Cushman‐Vokoun, William K. Funkhouser, Scott Kopetz, Christopher Hanyoung Lieu, Noralane M. Lindor, Bruce D. Minsky et al. · 2017 · Journal of Molecular Diagnostics
Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment
Ganjun Yu, Yanfeng Wu, Wenying Wang, Jia Xu, Xiaoping Lv, Xuetao Cao, Tao Wan · 2018 · Cellular and Molecular Immunology
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
Ibrahim Ragab Eissa, Itzel Bustos‐Villalobos, Toru Ichinose, Shigeru Matsumura, Yoshinori Naoe, Noriyuki Miyajima, Daishi Morimoto, Nobuaki Mukoyama, Zhiwen Wu, Maki Tanaka et al. · 2018 · Cancers
Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer
Shaakir Hasan, Paul B. Renz, Rodney E. Wegner, Gene Grant Finley, Moses S. Raj, Dulabh Kaur Monga, James McCormick, Alexander V. Kirichenko · 2018 · Annals of Surgery
Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Andrew P. Georgiadis, Jennifer N. Durham, Laurel A. Keefer, Bjarne R. Bartlett, Magdalena Zielonka, Derek M. Murphy, James Robert White, Steve Lu, Ellen L. Verner, Finey Ruan et al. · 2019 · Clinical Cancer Research
MSIsensor-Pro: Fast, Accurate, and Matched-Normal-Sample-Free Detection of Microsatellite Instability
Peng Jia, Xiaofei Yang, Li Guo, Bowen Liu, Jiadong Lin, Hao Liang, Jianyong Sun, Chengsheng Zhang, Kai Ye · 2020 · Genomics Proteomics & Bioinformatics
Single‐cell analyses reveal suppressive tumor microenvironment of human colorectal cancer
Yan Mei, Weiwei Xiao, Hao Hu, Guanming Lu, Lingdan Chen, Zhun Sun, Mengdie Lü, Wenhui Ma, Ting Jiang, Yuanhong Gao et al. · 2021 · Clinical and Translational Medicine
Predictive biomarkers of colon cancer immunotherapy: Present and future
Wanting Hou, Yi Cheng, Hong Zhu · 2022 · Frontiers in Immunology
Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)
Wensi Zhao, Jun Lei, Shaobo Ke, Yuan Chen, Jiping Xiao, Li Wang, Li Wang, Yiping Ren, Mohammed Alnaggar, Hu Qiu et al. · 2023 · EClinicalMedicine
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Blanca Homet Moreno, Jesse Meir Zaretsky, Ángel García-Díaz, Jennifer Tsoi, Giulia Parisi, Lídia Robert, Katrina M. Meeth, Abibatou Ndoye, Marcus Bosenberg, Ashani T. Weeraratna et al. · 2016 · Cancer Immunology Research
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Elizabeth M. Swisher · 2016 · Clinical Cancer Research
Targeting Immune Checkpoints in Cancer Therapy
Suzanne Louise Topalian · 2017 · JAMA
EMT and Treatment Resistance in Pancreatic Cancer
Nicola Gaianigo, Davide Melisi, Carmine Carbone · 2017 · Cancers
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Rimas Vincas Lukas, Jordi Ahnert Rodon, Kevin P. Becker, Eric T. Wong, Kent C. Shih, Mehdi Touat, Marcella Fassò, Stuart Osborne, Luciana Lorena Molinero, Carol Elaine O'Hear et al. · 2018 · Journal of Neuro-Oncology
A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer
Angela K. Green, Jacqueline Feinberg, Vicky Makker · 2020 · American Society of Clinical Oncology Educational Book
Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification
Soyoun Rachel Kim, Basile Tessier Cloutier, Samuel C. Y. Leung, Dawn R. Cochrane, Heidi M. Britton, Annick Orvoine Serra Pina, Claudine Storness-Bliss, David Farnell, Leo Huang, Kathryn Shum et al. · 2020 · Gynecologic Oncology
A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial
Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad‐Reza Rafiyan, Salah‐Eddin Al‐Batran, Mirjam Tariverdian, Elke Jäger, Magnus von Knebel Doeberitz · 2020 · Clinical Cancer Research
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
Yi Wang, Yuya Wang, Yifei Ren, Qi Zhang, Ping Yi, Chunming Cheng · 2022 · Seminars in Cancer Biology
Challenges in neoantigen-directed therapeutics
Lien Lybaert, Steve Lefever, Bruno Fant, Evelien Smits, Bruno G. De Geest, Karine Breckpot, Luc Yves Dirix, Steven A. Feldman, Wim Van Criekinge, Kris Thielemans et al. · 2022 · Cancer Cell
Therapeutic landscape and future direction of metastatic colorectal cancer
Hideaki Bando, Atsushi Ohtsu, Takayuki Yoshino · 2023 · Nature Reviews Gastroenterology & Hepatology
The role of immune checkpoint inhibition in the treatment of ovarian cancer
Stephanie L. Gaillard, Angeles Alvarez Secord, Bradley J. Monk · 2016 · Gynecologic Oncology Research and Practice
Clinical relevance of colorectal cancer molecular subtypes
Nuria Rodrı́guez-Salas, Gema Dominguez, Rodrigo Barderas, Marta Mendiola, Xabier García‐Albéniz, Joan Maurel, Jaime Feliú Batlle · 2016 · Critical Reviews in Oncology/Hematology
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors
Emily A. Sloan, Kari Lassen Ring, Brian C. Willis, Susan C. Modesitt, Anne M. Mills · 2016 · The American Journal of Surgical Pathology
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer
Amrendra Kumar, Reese Watkins, Anna E. Vilgelm · 2021 · Frontiers in Immunology
Mismatch repair deficiency: The what, how and why it is important
Maria Carolina Olave, Rondell Patrell Graham · 2021 · Genes Chromosomes and Cancer
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer
Yuanyuan Zhang, Hongyan Chen, Hongnan Mo, Ning Zhao, Xiaoying Sun, Baolin Liu, Ranran Gao, Binghe Xu, Zemin Zhang, Zhihua Liu et al. · 2025 · Cancer Cell
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Manav Korpal, Xiaoling Puyang, Zhenhua J. Wu, Roland Seiler, Craig Furman, Htoo Zarni Oo, Michael Seiler, Sean Irwin, Vanitha Subramanian, Jaya Julie Joshi et al. · 2017 · Nature Communications
Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer
Daniela Cornelia Lazăr, Mihaela Flavia Avram, Ioan Romosan, Mărioara Cornianu, Sorina Maria Tăban, Adrian Goldiș · 2018 · World Journal of Gastroenterology
The clinical promise of immunotherapy in triple-negative breast cancer
Praveen Vikas, Nicholas C. Borcherding, Weizhou Zhang · 2018 · Cancer Management and Research
Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens
Sandra Wagner, Christina Susanne Mullins, Michael Linnebacher · 2018 · World Journal of Gastroenterology
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu et al. · 2019 · Journal for ImmunoTherapy of Cancer
Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
Ángela Lamarca, Zainul Abedin Kapacee, Michael Breeze, Christopher Bell, Dean Belcher, Helen Staiger, Claire Taylor, Mairead Geraldine McNamara, Richard A Hubner, Juan W. Valle · 2020 · Journal of Clinical Medicine
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui et al. · 2021 · Frontiers in Oncology
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH)
Fan Xia, Yaqi Wang, Hui Wang, Lijun Shen, Zuo‐Lin Xiang, Yutian Zhao, Huojun Zhang, Juefeng Wan, Hui Zhang, Yan Wang et al. · 2024 · Journal of Clinical Oncology
Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Jiang, Yuming, Xie, Jingjing, Han, Zhen, Liu, Wei, Xi, Sujuan, Huang, Lei, Huang, Weicai, Lin, Tian, Zhao, Liying, Hu, Yanfeng et al. · 2018 · Clinical Cancer Research
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
Wolfgang Wick, Susan Dettmer, Anne Berberich, Tobias Keßler, Irini Karapanagiotou‐Schenkel, Antje Wick, Frank Winkler, Elke Pfaff, Benedikt Brors, Jürgen Debus et al. · 2018 · Neuro-Oncology
Current status of immunotherapy in metastatic colorectal cancer
Paweł Wróbel, Shahid Ahmed · 2018 · International Journal of Colorectal Disease
Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma
Chuanjie Zhang, Zongtai Li, Feng Qi, Xin Hu, Jun Luo · 2019 · Annals of Translational Medicine
IFNγ signaling integrity in colorectal cancer immunity and immunotherapy
Wan Du, Timothy L. Frankel, Michael Green, Weiping Zou · 2021 · Cellular and Molecular Immunology
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers
Chunhong Zheng, Joseph N Fass, Yi-Ping Shih, Andrew J. Gunderson, Nelson Sanjuan Silva, Huayu Huang, Brady M. Bernard, Venkatesh Rajamanickam, Joseph Slagel, Carlo Bruno Bifulco et al. · 2022 · Cancer Cell
Single‐Nucleus RNA Sequencing and Spatial Transcriptomics Reveal the Immunological Microenvironment of Cervical Squamous Cell Carcinoma
Zhihua Ou, Shitong Lin, Jiaying Qiu, Wencheng Ding, Peidi Ren, Dongsheng Chen, Jiaxuan Wang, Yihan Tong, Di Wu, Ao Chen et al. · 2022 · Advanced Science
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer
Sung Hee Lim, Min Eui Hong, Sung Woo Ahn, Yoon‐La Choi, K.-M. Kim, Dongryul Oh, Yong Chan Ahn, Sin‐Ho Jung, Myung‐Ju Ahn, K. Park et al. · 2015 · European Journal of Cancer
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
Tiana Kordbacheh, Jamie Honeychurch, Fiona Helen Blackhall, Corinne Faivre Finn, Tim Illidge · 2017 · Annals of Oncology
Recent advances in Lynch syndrome
Leah H. Biller, Sapna Syngal, Matthew B.B. Yurgelun · 2019 · Familial Cancer
Molecular Pathology of Colorectal Cancer
Shuko Harada, Diana M. Morlote · 2019 · Advances in Anatomic Pathology
JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
Takayuki Yoshino, G. Pentheroudakis, Saori Mishima, Michael James Overman, Kun‐Huei Yeh, Eishi Baba, Yoichi Naito, Fabien M. Calvo, Ajit Kumar Saxena, L.-T. Chen et al. · 2020 · Annals of Oncology
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
Yasuhiro Nakamura, Kenjiro Namikawa, Kenji Yoshino, Shusuke Yoshikawa, Hiroshi Uchi, K. Goto, Y. Nakamura, Satoshi Fukushima, Yukiko Kiniwa, Tatsuya Takenouchi et al. · 2020 · Annals of Oncology
An update on the immune landscape in lung and head and neck cancers
Jennifer Wilkinson Carlisle, Conor Ernst Steuer, Taofeek Kunle Owonikoko, Nabil F. Saba · 2020 · CA A Cancer Journal for Clinicians
Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC
Evelyn M. Nguyen, Hirokazu Taniguchi, Joseph Minhow Chan, Yingqian Ada Zhan, Xiaoping Chen, Juan Jan Qiu, Elisa de Stanchina, Viola Allaj, Nisargbhai Shah, Fathema Z. Uddin et al. · 2022 · Journal of Thoracic Oncology
Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases
Kevin M. Sullivan, Xiuyun Jiang, Prajna Guha, Christopher G. Lausted, Jason A. Carter, Cynthia L. Hsu, Kevin P. Labadie, Karan Kohli, Heidi L. Kenerson, Sara K. Daniel et al. · 2022 · Gut
High microsatellite instability (MSI-H) colorectal carcinoma: A brief review of predictive biomarkers in the era of personalized medicine
Gatalica, Zoran, Vranic, Semir, Xiu, Joanne, Swensen, Jeffrey, Reddy, Sandeep · 2016 · Familial Cancer
Drug discovery in advanced prostate cancer: translating biology into therapy
Timothy Anthony Yap, Alan David Smith, Roberta Ferraldeschi, Bissan Al‐Lazikani, Paul Workman, Johann Sebastian De Bono · 2016 · Nature Reviews Drug Discovery
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Robbie G. Majzner, Sabine Heitzeneder, Crystal Lee Mackall · 2017 · Cancer Cell
A review of soft-tissue sarcomas: translation of biological advances into treatment measures
Ngoc T. Hoang, Luis A. Acevedo, Michael J. Mann, Bhairavi Tolani · 2018 · Cancer Management and Research
How I treat biliary tract cancer
Ángela Lamarca, Julien Edeline, Lipika Goyal · 2022 · ESMO Open
Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature
Melissa Kristen Frey, Bhavana Pothuri · 2017 · Gynecologic Oncology Research and Practice
Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies
Florent Petitprez, Yann Alexandre Vano, Étienne Becht, Nicolás A. Giraldo, Aurélien de Reyniès, Catherine Sautès‐Fridman, Wolf H. Fridman · 2017 · Cancer Immunology Immunotherapy
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
Laëtitia Nebot-Bral, David Brandão, Loïc Verlingue, Étienne Rouleau, Olivier Caron, Emmanuelle Despras, Yolla El Dakdouki, Stéphane Champiat, Saïd Aoufouchi, Alexandra F. Leary et al. · 2017 · European Journal of Cancer
Adrenocortical carcinoma — towards genomics guided clinical care
Joakim Crona, Felix Beuschlein · 2019 · Nature Reviews Endocrinology
High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
Dedong Cao, Huilin Xu, Ximing Xu, Tao Guo, Wei Ge · 2019 · OncoImmunology
Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads
Danielle M. Lussier, Elise Alspach, Jeffrey P. Ward, Alexander P. Miceli, Daniele Runci, J. Michael White, Cedric Mpoy, Cora D. Arthur, Heather N. Kohlmiller, Tyler Jacks et al. · 2021 · Proceedings of the National Academy of Sciences
Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation
Wan Du, Fang Hua, Xiong Li, Jian Zhang, Shasha Li, Weichao Wang, Jiajia Zhou, Weimin Wang, Peng Liao, Yijian Yan et al. · 2021 · Cancer Discovery
Mass spectrometry-based antigen discovery for cancer immunotherapy
Michal Bassani‐Sternberg, George Coukos · 2016 · Current Opinion in Immunology
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia
Brenton G. Mar, S. Haihua Chu, Josephine D. Kahn, Andrei V. Krivtsov, Richard P. Koche, Cecilia A. Castellano, Jacob L. Kotlier, Rebecca L. Zon, Marie Ellen McConkey, Jonathan R. Chabon et al. · 2017 · Blood
Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
Dipti M. Karamchandani, Runjan Chetty · 2018 · Journal of Clinical Pathology
Cardiovascular complications of immune checkpoint inhibitors for cancer
Franck Thuny, Jarushka Naidoo, Tomas G. Neilan · 2022 · European Heart Journal
Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer
Yuki Ozato, Yasuhiro Kojima, Yuta Kobayashi, Yuuichi Hisamatsu, Takeo Toshima, Yusuke Yonemura, Takaaki Masuda, Kouichi Kagawa, Yasuhiro Goto, Mitsuaki Utou et al. · 2023 · Cell Reports
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
Ha Yeong Choi, Ji‐Eun Chang · 2023 · International Journal of Molecular Sciences
Combined Mutation of <i>Apc, Kras</i> , and <i>Tgfbr2</i> Effectively Drives Metastasis of Intestinal Cancer
Sakai, Eri, Nakayama, Mizuho, Oshima, Hiroko, Kouyama, Yuta, Niida, Atsushi, Fujii, Satoshi, Ochiai, Atsushi, Nakayama, Keiichi I., Mimori, Koshi, Suzuki, Yutaka et al. · 2018 · Cancer Research
Temozolomide in the Era of Precision Medicine
Anish Thomas, Mamoru Tanaka, Jane B. Trepel, William C. Reinhold, Vinodh N. Rajapakse, Yves G. Pommier · 2017 · Cancer Research
The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution
Alexej Ballhausen, Moritz Jakob Przybilla, Michael Jendrusch, Saskia Haupt, Elisabeth Pfaffendorf, Florian Seidler, Johannes Witt, Alejandro Hernandez‐Sanchez, Katharina Urban, Markus Draxlbauer et al. · 2020 · Nature Communications
Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer
Franceska Dedeurwaerdere, Kathleen Claes, Jo Van Dorpe, Isabelle Rottiers, Joni Van der Meulen, Joke Breyne, Koen Swaerts, Geert Antoine Martens · 2021 · Scientific Reports
The 2019 World Health Organization Classification of appendiceal, colorectal and anal canal tumours: an update and critical assessment
Mahsa Seyed Ahadi, Anna Sokolova, Ian Brown, Angela S. Y. Chou, Anthony James Gill · 2021 · Pathology
Intestinal bacteria and colorectal cancer: etiology and treatment
Michael W. Dougherty, Christian Jobin · 2023 · Gut Microbes
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Manisha Singh, Van Karlyle Morris, Irfan N. Bandey, David S. Hong, Scott Kopetz · 2024 · Trends in cancer
Precision oncology in the age of integrative genomics
Chandan Kumar‐Sinha, Arul M. Chinnaiyan · 2018 · Nature Biotechnology
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Anna Rachel Minchom, Caterina Aversa, Juanita Suzanne Lopez · 2018 · Therapeutic Advances in Medical Oncology